4 results
To determine appropriate dosing regimens for use in future clinical trials of GS 9820 in subjects with lymphoid malignancies.
To evaluate whether dGEMRIC is suitable as outcome measure to detect changes over time, and also between intervention groups in patients with OA of the knee.
To assess whether there is (cost) effectiveness over a period of 1 year of additive intra-articular injections with a high molecular HA derivate in patients with OA of the knee.
Determine the priming effect on the epileptic brain of tVNS, to make it more susceptible to treatment with Brivaracetam (BRV), an AED. In addition, we aim to visualize these changes in the brain because of priming, possibly altered network-…